Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 284 results
A vial of liquid medication on a laboratory countertop in a dimly lit setting.

Jul 20, 2026

Bristol Myers Squibb becomes latest company to claim it’s building pharma’s largest NVIDIA AI supercomputer

Bristol Myers Squibb (BMS) has joined the trend of pharmaceutical companies announcing the construction of large AI supercomputers, marking a significant step in leveraging advanced computational power for drug development.In a recent announcement, BMS revealed its plans to build what it claims will be the largest AI supercomputer in the life sciences sector. This follows similar declarations from other pharma companies within the past nine months. Initially, BMS partnered with NVIDIA three year
A flat design of a drug molecule silhouette

Jul 19, 2026

AI-Driven Discovery Platforms

Takeda has entered a strategic partnership with Insilico Medicine to leverage the Pharma AI suite for early-stage drug discovery across various therapeutic areas.This collaboration grants Takeda exclusive global rights to develop, manufacture, and commercialize drug candidates identified through Insilico's AI-driven discovery process. Insilico will spearhead the discovery phase, while Takeda will take selected therapies into clinical development.The Pharma.AI suite encompasses tools such as Pand
A flat illustration of a molecule representing retrosynthesis in a minimalist style.

Jul 17, 2026

Retrosynthesis software bridges pharma agrochemicals and fragrance sectors with advanced route design

Recent advancements in retrosynthesis software are revolutionizing the way chemists across pharmaceuticals, agrochemicals, and fragrance industries approach synthetic route design. Platforms like SYNTHIA utilize expert-coded reaction rules along with extensive chemical libraries to facilitate the synthesis of complex molecules. This technology significantly enhances the efficiency of the design process, allowing for more innovative solutions in drug development, agricultural chemicals, and fragr
Flat design illustration of a drug compound and clinical trial symbol

Jul 17, 2026

How well are AI-discovered drugs faring in the clinic?

The integration of AI in drug discovery is still in its nascent stages, with mixed results in clinical trials. While AI has the potential to revolutionize the pharmaceutical landscape, the journey from AI-driven discovery to clinical success is fraught with challenges.AI has emerged as a promising tool for accelerating drug research and development, traditionally a lengthy and expensive process. Although some AI-discovered drugs have shown early promise in phase 1 trials, their performance in la
A minimalist representation of a biological sample in a dark color scheme.

Jul 17, 2026

Antwerp’s Sightera Biosciences raises €3 million to scale its patient-derived AI drug discovery platform

Sightera Biosciences, a startup based in Antwerp, has successfully secured €3 million in pre-Seed funding to enhance its AI-driven drug discovery platform, which focuses on patient-derived biological data. This financing round was led by Entourage, Anacura, and QBIC, and the company aims to expand its team and accelerate the development of its oncology and fibrosis programs.The innovative approach of Sightera lies in its unique training methodology for its AI models. Instead of relying on generi
A test tube with antibody solution on a lab table

Jul 17, 2026

Argenx Partners With Chai Discovery for AI Antibody...

Chai Discovery has partnered with argenx to leverage AI for antibody discovery, marking a significant advancement in the life sciences sector.Chai Discovery, based in San Francisco, has formed a collaboration with argenx, providing the immunology firm with early access to its generative AI platform aimed at de novo antibody discovery. This partnership is notable as it is the fourth disclosed collaboration for Chai within a span of seven months, following similar agreements with major pharmaceuti
A close-up of an organoid culture dish in a dimly lit lab, highlighting the intricate details of the tissue sample.

Jul 17, 2026

Reversing AI drug discovery: Belgian biotech Sightera raises €3M to learn from 'extreme' patient biology first

Belgian biotech Sightera Biosciences has secured €3 million in pre-seed funding to advance its innovative AI drug discovery platform, which uniquely focuses on learning from treatment-resistant patients.Sightera's approach diverges from conventional AI drug discovery methods by starting with data from patients who do not respond to standard treatments. This "extreme biology" strategy involves creating organoids from these patients' tissues and conducting high-throughput drug screenings to gather
A minimalist illustration of a surgical robot arm and scalpel on a dark background.

Jul 16, 2026

Japan overhauls healthcare and life sciences with Nvidia AI

Japan is set to revolutionize its healthcare and life sciences sectors through the integration of AI technologies, particularly leveraging Nvidia's innovations.Recent discussions led by Nvidia CEO Jensen Huang highlighted Japan's commitment to advancing medical technology with AI-driven solutions. The country is actively implementing autonomous surgical robots, AI-enhanced imaging systems, and innovative drug discovery platforms. A notable initiative is the Tokyo-1 consortium, which unites major
A laboratory vial containing a drug compound in a dimly lit lab setting.

Jul 15, 2026

Bora Pharmaceuticals and Insilico Medicine Strike a $2.5 Billion AI Alliance

Bora Pharmaceuticals and Insilico Medicine have entered a significant partnership aimed at revolutionizing AI-driven drug development, with a potential value exceeding $2.5 billion.This collaboration, announced during BIO Asia-Taiwan, marks a pivotal shift in the pharmaceutical landscape, focusing on integrating AI not just in drug discovery but also in manufacturing processes. Insilico's Pharma.AI platform, which encompasses tools for target discovery and clinical insights, will be paired with
A minimalist representation of a TNIK inhibitor molecule in a dark color scheme.

Jul 15, 2026

Insilico & Bora Partner on AI Drug Discovery

Insilico Medicine and Bora Pharmaceuticals have formed a strategic alliance aimed at enhancing AI-driven drug discovery and development.The partnership leverages Insilico's Pharma.AI platform, which integrates target identification, generative chemistry, and multi-parameter optimization. Since its inception in 2021, this platform has successfully generated 31 preclinical candidates, with 13 receiving IND approvals. Notably, one standout asset is ISM018_055, an AI-generated TNIK inhibitor current
A vial of a drug compound in a dimly lit laboratory setting.

Jul 15, 2026

Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development

Insilico Medicine and Bora Pharmaceuticals are poised to form a strategic alliance aimed at revolutionizing drug discovery and development through AI technologies.The proposed collaboration is anticipated to be valued at over $2.5 billion if fully realized. It aims to integrate Insilico's Pharma.AI platform—which specializes in target discovery, generative chemistry, and molecule optimization—with Bora's extensive capabilities in drug development, manufacturing, and commercialization. This partn
A minimalist illustration of a pill bottle and an AI chip on a dark background.

Jul 15, 2026

Bora, Insilico Launch Multi-Target AI Pharma Alliance

Insilico Medicine has formed a strategic alliance with Bora Pharmaceuticals to integrate AI into drug discovery and development.Insilico Medicine, known for its generative AI-driven approach to drug discovery, has partnered with Bora Pharmaceuticals to create a multi-target alliance. This collaboration aims to merge Insilico’s Pharma.AI platform with Bora’s extensive capabilities in global development, manufacturing, and commercialization. The goal is to innovate drug development by linking AI-e